Freshfields advises STADA on public delisting purchase offer by Bain Capital and CinvenFreshfields Bruckhaus Deringer is advising STADA Arzneimittel AG ("STADA") on the public delisting purchase offer for the STADA shares by Bain Capital and Cinven. The offer price is expected to amount to EUR 81.83 per STADA share. The total offer is expected to amount to approximately EUR 1.8 bn.
On 1 October 2018, Nidda Healthcare GmbH, Bain Capital and Cinven's acquisition vehicle, announced its intention to publish a delisting purchase offer. Moreover, STADA's Executive Board was instructed to apply to revoke the admission of all shares and bonds for trading. The delisting from the stock exchange shall cut the costs associated with the stock exchange listing for STADA and reduce the regulatory effort.
Freshfields Bruckhaus Deringer has been comprehensively advising STADA since the mid-May 2016; at that time regarding corporate governance claims made by activist shareholders as well as in 2017 on the legal structuring of the bidding process, on the process of the public takeover by Bain Capital and Cinven as well as on the conclusion of the domination and profit transfer agreement effective since March 2018. In addition, this year, Freshfields advised STADA on the refinancing and change of the terms of the bonds issued by STADA.
The Freshfields-team comprises Christoph H. Seibt, Sabrina Kulenkamp and Moritz Diekgräf (all Corporate/M&A).
Notes for editors
Freshfields Bruckhaus Deringer LLP is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on ground-breaking and business-critical mandates. Our 2,800 plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multi-national expertise and business know-how means our clients rely on us when it matters most.